Real-world study of lenvatinib in patients with radioiodine‑refractory thyroid cancer treated in a tertiary reference center
This retrospective analysis of a Polish RAIR thyroid cancer cohort demonstrated very good efficacy of lenvatinib in the first-line setting, while its activity in the second-line setting, although still present, was reduced. Based on these results, we suggest that lenvatinib should again be available for the treatment of RAIR thyroid cancer in Poland.
Authors
- Barbara Jarząb (ORCID: https://orcid.org/0000-0001-9811-9584)
- Magdalena Kolton
- Aleksandra Kukulska (ORCID: https://orcid.org/0000-0002-4909-9190)
- Jolanta Krajewska (ORCID: https://orcid.org/0000-0003-0479-4998)
- Katarzyna Drosik‐Rutowicz
- Aleksandra Król (ORCID: https://orcid.org/0000-0002-2084-5014)
- Agata Wilk (ORCID: https://orcid.org/0000-0001-7554-1803)
- Daria Handkiewicz-Junak (ORCID: https://orcid.org/0000-0003-2322-7454)
Institutions
- National Institute of Oncology (HU)
- The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
Publication Details
- Journal
- Endokrynologia Polska
- Published
- 2025-12-03
- DOI
- https://doi.org/10.5603/ep.109670
- Primary Topic
- Thyroid Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00